Publications

Metrics

Google Scholar • Scopus • UCL Iris • ORCiD

Book chapters 6
Journal articles 91
Total citations 16,889
h-index 56
i10-index 101

Last updated December 2023

Book

Patient 1: Forgetting and finding myself – with Charlotte Raven. Jonathan Cape (Penguin), 2021

Book chapters

  1. Biofluid Biomarkers for Huntington’s Disease
    F Rodrigues, L Byrne & E Wild
    In Methods in Molecular Biology: Huntington’s Disease
    eds. Precious, Rosser & Dunnett. Springer, 2018.
  2. Premanifest and Early Huntington’s Disease
    E Wild & S Tabrizi.
    In Huntington’s Disease (Oxford Monographs on Medical Genetics), 3rd ed. Eds G Bates, L Jones & S Tabrizi. Oxford University Press, 2015.
  3. Huntington’s Disease & Other Choreas
    S Haider, E Wild & S Tabrizi.
    In Neurodegeneration, ed. A Schapira. Wiley, 2014.
  4. Huntington’s disease look-alike syndromes
    E Wild & S Tabrizi.
    In Oxford Textbooks in Clinical Neurology: Movement Disorders (2nd edition), ed. D Burn. Oxford University Press, 2013.
  5. Huntington’s Disease
    S Tabrizi & E Wild
    In Neurogenetics: A Guide for Clinicians (2nd edition), ed. N Wood. Cambridge University Press, 2012
  6. Huntington’s Disease and Dementia
    E Wild, N Hobbs & S Henley.
    In Neuroimaging in Dementia (1st edition), ed. F Barkhof, J Valk & N Fox. Springer-Verlag, 2011

PhD Thesis

Identification and evaluation of biomarkers for Huntington’s disease, 2009. University College London.

Peer-reviewed journal articles

  1. Potential disease-modifying therapies for Huntington’s disease: lessons learned and future opportunities.
     The Lancet Neurology (2022) 21, 645-658.
    Tabrizi, S. J., Estevez-Fraga, C., van Roon-Mom, W. M. C., Flower, M. D., Scahill, R. I., Wild, E. J., Muñoz-Sanjuan, I., Sampaio, C., Rosser, A. E. and Leavitt, B. R.
  2. Huntington’s Disease Clinical Trials Corner: April 2022.
     J Huntingtons Dis (2022) 11, 105-118.
    Estevez-Fraga, C., Rodrigues, F. B., Tabrizi, S. J. and Wild, E. J.
  3. Natural History and Burden of Huntington’s Disease in the UK: A Population-Based Cohort Study.
     Eur J Neurol (2022).
    Furby, H., Siadimas, A., Rutten-Jacobs, L., Rodrigues, F. B. and Wild, E. J.
  4. CAG Somatic Instability in a Huntington Disease Expansion Carrier Presenting with a Progressive Supranuclear Palsy-like Phenotype.
     Mov Disord (2022).
    Dewan, R., Jaunmuktane, Z., Garcia-Segura, M. E., Strand, C., Wild, E., Villar, J., Dalgard, C. L., Tabrizi, S. J., Traynor, B. J. and Proukakis, C.
  5. Neurofilament Light Protein as a Potential Blood Biomarker for Huntington’s Disease in Children.
     Mov Disord (2022).
    Byrne, L. M., Schultz, J. L., Rodrigues, F. B., van der Plas, E., Langbehn, D., Nopoulos, P. C. and Wild, E. J.
  6. Safety and Feasibility of Research Lumbar Puncture in Huntington’s Disease: The HDClarity Cohort and Bioresource.
     J Huntingtons Dis (2022) 11, 59-69.
    Rodrigues, F. B., Owen, G., Sathe, S., Pak, E., Kaur, D., Ehrhardt, A. G., Lifer, S., Townhill, J., Schubert, K., Leavitt, B. R., Guttman, M., Bang, J., Lewerenz, J., Levey, J., Sampaio, C. and Wild, E. J.
  7. Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington’s disease.
     J Neurochem (2021).
    Rodrigues, F. B., Byrne, L. M., Lowe, A. J., Tortelli, R., Heins, M., Flik, G., Johnson, E. B., De Vita, E., Scahill, R. I., Giorgini, F. and Wild, E. J.
  8. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease.
     Scientific Reports (2021) 11, 3481.
    Ou, Z.-Y. A., Byrne, L. M., Rodrigues, F. B., Tortelli, R., Johnson, E. B., Foiani, M. S., Arridge, M., De Vita, E., Scahill, R. I., Heslegrave, A., Zetterberg, H. and Wild, E. J.
  9. Estimating the causal effects of modifiable, non-genetic factors on Huntington disease progression using propensity score weighting.
     Parkinsonism & Related Disorders (2021) 83, 56-62.
    Griffin, B. A., Booth, M. S., Busse, M., Wild, E. J., Setodji, C., Warner, J. H., Sampaio, C. and Mohan, A.
  10. The use of wearable/portable digital sensors in Huntington’s disease: A systematic review.
     Parkinsonism & Related Disorders (2021) 83, 93-104.
    Tortelli, R., Rodrigues, F. B. and Wild, E. J.
  11. Huntington’s disease mice and human brain tissue exhibit increased G3BP1 granules and TDP43 mislocalization.
     The Journal of Clinical Investigation (2021) 131.
    Sanchez, I. I., Nguyen, T. B., England, W. E., Lim, R. G., Vu, A. Q., Miramontes, R., Byrne, L. M., Markmiller, S., Lau, A. L., Orellana, I., Curtis, M. A., Faull, R. L. M., Yeo, G. W., Fowler, C. D., Reidling, J. C., Wild, E. J., Spitale, R. C. and Thompson, L. M.
  12. Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington’s disease Young Adult Study (HD-YAS): a cross-sectional analysis.
     Lancet Neurol (2020) 19, 502-512.
    Scahill, R. I., Zeun, P., Osborne-Crowley, K., Johnson, E. B., Gregory, S., Parker, C., Lowe, J., Nair, A., O’Callaghan, C., Langley, C., Papoutsi, M., McColgan, P., Estevez-Fraga, C., Fayer, K., Wellington, H., Rodrigues, F. B., Byrne, L. M., Heselgrave, A., Hyare, H., Sampaio, C., Zetterberg, H., Zhang, H., Wild, E. J., Rees, G., Robbins, T. W., Sahakian, B. J., Langbehn, D. and Tabrizi, S. J.
  13. Characterizing White Matter in Huntington’s Disease.
     Mov Disord Clin Pract (2020) 7, 52-60.
    Gregory, S., Johnson, E., Byrne, L. M., Rodrigues, F. B., Henderson, A., Moss, J., Thomas, D., Zhang, H., De Vita, E., Tabrizi, S. J., Rees, G., Scahill, R. I. and Wild, E. J.
  14. Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities.
     Nat Rev Neurol (2020).
    Tabrizi, S. J., Flower, M. D., Ross, C. A. and Wild, E. J.
  15. Neuropsychiatric comorbidities in Huntington’s and Parkinson’s Disease: A United States claims database analysis.
     Annals of Clinical and Translational Neurology (2020) n/a.
    Ishihara, L., Oliveri, D. and Wild, E. J.
  16. Mutant huntingtin is cleared from the brain via active mechanisms in Huntington disease.
     The Journal of Neuroscience (2020), JN-RM-1865-1820.
    Caron, N. S., Banos, R., Yanick, C., Aly, A. E., Byrne, L. M., Smith, E. D., Xie, Y., Smith, S. E. P., Potluri, N., Findlay Black, H., Casal, L., Ko, S., Cheung, D., Kim, H., Seong, I. S., Wild, E. J., Song, J.-J., Hayden, M. R. and Southwell, A. L.
  17. Huntington’s Disease Clinical Trials Corner: April 2020.
     J Huntingtons Dis (2020) 9, 185-197.
    Rodrigues, F. B. and Wild, E. J.
  18. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington’s disease.
     Science Translational Medicine (2020) 12, eabc2888.
    Rodrigues, F. B., Byrne, L. M., Tortelli, R., Johnson, E. B., Wijeratne, P. A., Arridge, M., De Vita, E., Ghazaleh, N., Houghton, R., Furby, H., Alexander, D. C., Tabrizi, S. J., Schobel, S., Scahill, R. I., Heslegrave, A., Zetterberg, H. and Wild, E. J.
  19. Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington’s disease.
     PLoS One (2020) 15, e0233820.
    Lowe, A. J., Sjodin, S., Rodrigues, F. B., Byrne, L. M., Blennow, K., Tortelli, R., Zetterberg, H. and Wild, E. J.
  20. One decade ago, one decade ahead in huntington’s disease.
     Mov Disord (2019) 34, 1434-1439.
    Wild, E. J. and Tabrizi, S. J.
  21. Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.
     JAMA Neurol (2019).
    Bridel, C., van Wieringen, W. N., Zetterberg, H., Tijms, B. M., Teunissen, C. E., and the, N. F. L. G., Alvarez-Cermeno, J. C., Andreasson, U., Axelsson, M., Backstrom, D. C., Bartos, A., Bjerke, M., Blennow, K., Boxer, A., Brundin, L., Burman, J., Christensen, T., Fialova, L., Forsgren, L., Frederiksen, J. L., Gisslen, M., Gray, E., Gunnarsson, M., Hall, S., Hansson, O., Herbert, M. K., Jakobsson, J., Jessen-Krut, J., Janelidze, S., Johannsson, G., Jonsson, M., Kappos, L., Khademi, M., Khalil, M., Kuhle, J., Landen, M., Leinonen, V., Logroscino, G., Lu, C. H., Lycke, J., Magdalinou, N. K., Malaspina, A., Mattsson, N., Meeter, L. H., Mehta, S. R., Modvig, S., Olsson, T., Paterson, R. W., Perez-Santiago, J., Piehl, F., Pijnenburg, Y. A. L., Pyykko, O. T., Ragnarsson, O., Rojas, J. C., Romme Christensen, J., Sandberg, L., Scherling, C. S., Schott, J. M., Sellebjerg, F. T., Simone, I. L., Skillback, T., Stilund, M., Sundstrom, P., Svenningsson, A., Tortelli, R., Tortorella, C., Trentini, A., Troiano, M., Turner, M. R., van Swieten, J. C., Vagberg, M., Verbeek, M. M., Villar, L. M., Visser, P. J., Wallin, A., Weiss, A., Wikkelso, C. and Wild, E. J.
  22. Targeting Huntingtin Expression in Patients with Huntington’s Disease.
     N Engl J Med (2019) 380, 2307-2316.
    Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., Rosser, A., Kordasiewicz, H. B., Czech, C., Swayze, E. E., Norris, D. A., Baumann, T., Gerlach, I., Schobel, S. A., Paz, E., Smith, A. V., Bennett, C. F., Lane, R. M. and Phase 1-2a, I.-H. S. S. T.
  23. Cerebrospinal fluid flow dynamics in Huntington’s disease evaluated by phase contrast MRI.
     Eur J Neurosci (2019) 49, 1632-1639.
    Rodrigues, F. B., Byrne, L. M., De Vita, E., Johnson, E. B., Hobbs, N. Z., Thornton, J. S., Scahill, R. I. and Wild, E. J.
  24. Fluid and imaging biomarkers for Huntington’s disease.
     Mol Cell Neurosci (2019) 97, 67-80.
    Zeun, P., Scahill, R. I., Tabrizi, S. J. and Wild, E. J.
  25. Comparison of the Huntington’s Disease like 2 and Huntington’s Disease Clinical Phenotypes.
     Mov Disord Clin Pract (2019) 6, 302-311.
    Anderson, D. G., Ferreira-Correia, A., Rodrigues, F. B., Aziz, N. A., Carr, J., Wild, E. J., Margolis, R. L. and Krause, A.
  26. Huntington’s Disease Clinical Trials Corner: June 2019.
     J Huntingtons Dis (2019) 8, 363-371.
    Rodrigues, F. B., Ferreira, J. J. and Wild, E. J.
  27. Huntington’s Disease Clinical Trials Corner: January 2019.
     J Huntingtons Dis (2019) 8, 115-125.
    Rodrigues, F. B., Quinn, L. and Wild, E. J.
  28. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington’s disease.
     Sci Transl Med (2018) 10.
    Byrne, L. M., Rodrigues, F. B., Johnson, E. B., Wijeratne, P. A., De Vita, E., Alexander, D. C., Palermo, G., Czech, C., Schobel, S., Scahill, R. I., Heslegrave, A., Zetterberg, H. and Wild, E. J.
  29. Physician perception versus true efficacy of tetrabenazine for Huntington’s disease.
     Curr Med Res Opin (2018) 34, 1537-1538.
    Rodrigues, F. B., Ferreira, J. J. and Wild, E. J.
  30. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series.
     Mol Psychiatry (2018).
    Koriath, C., Kenny, J., Adamson, G., Druyeh, R., Taylor, W., Beck, J., Quinn, L., Mok, T. H., Dimitriadis, A., Norsworthy, P., Bass, N., Carter, J., Walker, Z., Kipps, C., Coulthard, E., Polke, J. M., Bernal-Quiros, M., Denning, N., Thomas, R., Raybould, R., Williams, J., Mummery, C. J., Wild, E. J., Houlden, H., Tabrizi, S. J., Rossor, M. N., Hummerich, H., Warren, J. D., Rowe, J. B., Rohrer, J. D., Schott, J. M., Fox, N. C., Collinge, J. and Mead, S.
  31. Perinatal insults and neurodevelopmental disorders may impact Huntington’s disease age of diagnosis.
     Parkinsonism Relat Disord (2018) 55, 55-60.
    Barkhuizen, M., Rodrigues, F. B., Anderson, D. G., Winkens, B., Network, R. I. o. t. E. H. s. D., Wild, E. J., Kramer, B. W. and Gavilanes, A. W. D.
  32. Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease.
     Sci Rep (2018) 8, 4260.
    Byrne, L. M., Rodrigues, F. B., Johnson, E. B., De Vita, E., Blennow, K., Scahill, R., Zetterberg, H., Heslegrave, A. and Wild, E. J.
  33. Neurofilament light protein in blood predicts regional atrophy in Huntington disease.
     Neurology (2018) 90, e717-e723.
    Johnson, E. B., Byrne, L. M., Gregory, S., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A., Zetterberg, H., Tabrizi, S. J., Scahill, R. I., Wild, E. J. and Group, T.-H. S.
  34. Huntington’s Disease Clinical Trials Corner: August 2018.
     J Huntingtons Dis (2018) 7, 279-286.
    Rodrigues, F. B. and Wild, E. J.
  35. Huntington’s Disease Clinical Trials Corner: February 2018.
     J Huntingtons Dis (2018) 7, 89-98.
    Rodrigues, F. B. and Wild, E. J.
  36. Biofluid Biomarkers in Huntington’s Disease.
     Methods Mol Biol (2018) 1780, 329-396.
    Rodrigues, F. B., Byrne, L. M. and Wild, E. J.
  37. Neurofilament light protein in CSF and blood is associated with neurodegeneration and disease severity in Huntington’s disease R6/2 mice.
     Sci Rep (2017) 7, 14114.
    Soylu-Kucharz, R., Sandelius, A., Sjogren, M., Blennow, K., Wild, E. J., Zetterberg, H. and Bjorkqvist, M.
  38. Therapies targeting DNA and RNA in Huntington’s disease.
     Lancet Neurol (2017) 16, 837-847.
    Wild, E. J. and Tabrizi, S. J.
  39. Tetrabenazine Versus Deutetrabenazine for Huntington’s Disease: Twins or Distant Cousins?
     Mov Disord Clin Pract (2017) 4, 582-585.
    Rodrigues, F. B., Duarte, G. S., Costa, J., Ferreira, J. J. and Wild, E. J.
  40. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis.
     Lancet Neurol (2017) 16, 601-609.
    Byrne, L. M., Rodrigues, F. B., Blennow, K., Durr, A., Leavitt, B. R., Roos, R. A. C., Scahill, R. I., Tabrizi, S. J., Zetterberg, H., Langbehn, D. and Wild, E. J.
  41. Ghost Pills: A Case Report.
     Ann Intern Med (2017) 166, 609.
    Salanio, D. M., Taylor, R., Stanton, J. E. D. and Wild, E. J.
  42. Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays.
     PLoS ONE (2017) 12, e0189891.
    Hensman Moss, D. J., Robertson, N., Farmer, R., Scahill, R. I., Haider, S., Tessari, M. A., Flynn, G., Fischer, D. F., Wild, E. J., Macdonald, D. and Tabrizi, S. J.
  43. Clinical Trials Corner: September 2017.
     J Huntingtons Dis (2017) 6, 255-263.
    Rodrigues, F. B. and Wild, E. J.
  44. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease”.
     J Clin Mov Disord (2017) 4, 19.
    Rodrigues, F. B., Duarte, G. S., Costa, J., Ferreira, J. J. and Wild, E. J.
  45. Validation of Ultrasensitive Mutant Huntingtin Detection in Human Cerebrospinal Fluid by Single Molecule Counting Immunoassay.
     J Huntingtons Dis (2017) 6, 349-361.
    Fodale, V., Boggio, R., Daldin, M., Cariulo, C., Spiezia, M. C., Byrne, L. M., Leavitt, B. R., Wild, E. J., Macdonald, D., Weiss, A. and Bresciani, A.
  46. Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease.
     J Neurochem (2016) 139, 22-25.
    Rodrigues, F. B., Byrne, L., McColgan, P., Robertson, N., Tabrizi, S. J., Leavitt, B. R., Zetterberg, H. and Wild, E. J.
  47. Huntington’s Disease: The Most Curable Incurable Brain Disorder?
     EBioMedicine (2016) 8, 3-4.
    Wild, E. J.
  48. Psychogenic non-epileptic seizures in early Huntington’s disease.
     Pract Neurol (2016) 16, 452-454.
    Rodrigues, F. B. and Wild, E. J.
  49. George Huntington: a legacy of inquiry, empathy and hope.
     Brain (2016) 139, 2326-2333.
    Wexler, A., Wild, E. J. and Tabrizi, S. J.
  50. Cerebrospinal Fluid Biomarkers for Huntington’s Disease.
     J Huntingtons Dis (2016) 5, 1-13.
    Byrne, L. M. and Wild, E. J.
  51. Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington’s Disease.
     PLoS ONE (2016) 11, e0163479.
    Rodrigues, F. B., Byrne, L. M., McColgan, P., Robertson, N., Tabrizi, S. J., Zetterberg, H. and Wild, E. J.
  52. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients.
     J Clin Invest (2015) 125, 1979-1986.
    Wild, E. J., Boggio, R., Langbehn, D., Robertson, N., Haider, S., Miller, J. R., Zetterberg, H., Leavitt, B. R., Kuhn, R., Tabrizi, S. J., Macdonald, D. and Weiss, A.
  53. Huntington disease.
     Nat Rev Dis Primers (2015) 1, 15005.
    Bates, G. P., Dorsey, R., Gusella, J. F., Hayden, M. R., Kay, C., Leavitt, B. R., Nance, M., Ross, C. A., Scahill, R. I., Wetzel, R., Wild, E. J. and Tabrizi, S. J.
  54. Targets for future clinical trials in Huntington’s disease: what’s in the pipeline?
     Mov Disord (2014) 29, 1434-1445.
    Wild, E. J. and Tabrizi, S. J.
  55. C9orf72 expansions are the most common genetic cause of Huntington disease phenocopies.
     Neurology (2014) 82, 292-299.
    Hensman Moss, D. J., Poulter, M., Beck, J., Hehir, J., Polke, J. M., Campbell, T., Adamson, G., Mudanohwo, E., McColgan, P., Haworth, A., Wild, E. J., Sweeney, M. G., Houlden, H., Mead, S. and Tabrizi, S. J.
  56. Huntington disease: natural history, biomarkers and prospects for therapeutics.
     Nat Rev Neurol (2014) 10, 204-216.
    Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., Reilmann, R., Unschuld, P. G., Wexler, A., Margolis, R. L. and Tabrizi, S. J.
  57. JAK/STAT Signalling in Huntington’s Disease Immune Cells.
     PLoS Curr (2013) 5.
    Trager, U., Magnusson, A., Lahiri Swales, N., Wild, E., North, J., Lowdell, M. and Bjorkqvist, M.
  58. Biomarkers for Huntington’s disease: an update.
     Expert Opin Med Diagn (2012) 6, 371-375.
    Scahill, R. I., Wild, E. J. and Tabrizi, S. J.
  59. Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression.
     J Clin Invest (2012) 122, 3731-3736.
    Weiss, A., Trager, U., Wild, E. J., Grueninger, S., Farmer, R., Landles, C., Scahill, R. I., Lahiri, N., Haider, S., Macdonald, D., Frost, C., Bates, G. P., Bilbe, G., Kuhn, R., Andre, R. and Tabrizi, S. J.
  60. HDBuzz: empowering patients through accessible education.
     Trends Mol Med (2012) 18, 1-3.
    Wild, E. J. and Carroll, J. B.
  61. Huntington’s disease: fighting on many fronts.
     Brain (2012) 135, 998-1001.
    Andre, R., Wild, E. J. and Tabrizi, S. J.
  62. Mutant huntingtin causes defective actin remodeling during stress: defining a new role for transglutaminase 2 in neurodegenerative disease.
     Human Molecular Genetics (2011) 20, 1937-1951.
    Munsie, L., Caron, N., Atwal, R. S., Marsden, I., Wild, E. J., Bamburg, J. R., Tabrizi, S. J. and Truant, R.
  63. Observing Huntington’s disease: the European Huntington’s Disease Network’s REGISTRY.
     J Neurol Neurosurg Psychiatry (2011) 82, 1409-1412.
    Orth, M., European Huntington’s Disease, N., Handley, O. J., Schwenke, C., Dunnett, S., Wild, E. J., Tabrizi, S. J. and Landwehrmeyer, G. B.
  64. Brain-derived neurotrophic factor in patients with Huntington’s disease.
     PLoS ONE (2011) 6, e22966.
    Zuccato, C., Marullo, M., Vitali, B., Tarditi, A., Mariotti, C., Valenza, M., Lahiri, N., Wild, E. J., Sassone, J., Ciammola, A., Bachoud-Levi, A. C., Tabrizi, S. J., Di Donato, S. and Cattaneo, E.
  65. Abnormal peripheral chemokine profile in Huntington’s disease.
     PLoS Curr (2011) 3, Rrn1231.
    Wild, E., Magnusson, A., Lahiri, N., Krus, U., Orth, M., Tabrizi, S. J. and Bjorkqvist, M.
  66. Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY.
     PLoS Curr (2010) 2, RRN1184.
    Orth, M., Handley, O. J., Schwenke, C., Dunnett, S. B., Craufurd, D., Ho, A. K., Wild, E., Tabrizi, S. J., Landwehrmeyer, G. B. and Investigators of the European Huntington’s Disease, N.
  67. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease.
     Mov Disord (2010) 25, 888-895.
    Wild, E. J., Henley, S. M., Hobbs, N. Z., Frost, C., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  68. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study.
     AJNR Am J Neuroradiol (2010) 31, 1036-1041.
    Hobbs, N. Z., Barnes, J., Frost, C., Henley, S. M., Wild, E. J., Macdonald, K., Barker, R. A., Scahill, R. I., Fox, N. C. and Tabrizi, S. J.
  69. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study.
     J Neurol Neurosurg Psychiatry (2010) 81, 756-763.
    Hobbs, N. Z., Henley, S. M., Ridgway, G. R., Wild, E. J., Barker, R. A., Scahill, R. I., Barnes, J., Fox, N. C. and Tabrizi, S. J.
  70. Harnessing immune alterations in neurodegenerative diseases.
     Neuron (2009) 64, 21-24.
    Björkqvist, M., Wild, E. J. and Tabrizi, S. J.
  71. Automated quantification of caudate atrophy by local registration of serial MRI: evaluation and application in Huntington’s disease.
     Neuroimage (2009) 47, 1659-1665.
    Hobbs, N. Z., Henley, S. M., Wild, E. J., Leung, K. K., Frost, C., Barker, R. A., Scahill, R. I., Barnes, J., Tabrizi, S. J. and Fox, N. C.
  72. Relationship between CAG repeat length and brain volume in premanifest and early Huntington’s disease.
     J Neurol (2009) 256, 203-212.
    Henley, S. M., Wild, E. J., Hobbs, N. Z., Scahill, R. I., Ridgway, G. R., Macmanus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  73. Whole-brain atrophy as a measure of progression in premanifest and early Huntington’s disease.
     Mov Disord (2009) 24, 932-936.
    Henley, S. M., Wild, E. J., Hobbs, N. Z., Frost, C., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  74. Serial volumetric MRI in Parkinsonian disorders.
     Mov Disord (2009) 24 Suppl 2, S691-698.
    Wild, E. J. and Fox, N. C.
  75. Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease.
     Brain (2008) 131, 2851-2859.
    Leoni, V., Mariotti, C., Tabrizi, S. J., Valenza, M., Wild, E. J., Henley, S. M., Hobbs, N. Z., Mandelli, M. L., Grisoli, M., Bjorkhem, I., Cattaneo, E. and Di Donato, S.
  76. Biomarkers for Huntington’s disease.
     Expert Opin Med Diagn (2008) 2, 47-62.
    Wild, E. J. and Tabrizi, S. J.
  77. Immune markers for Huntington’s disease?
     Expert Rev Neurother (2008) 8, 1779-1781.
    Wild, E., Bjorkqvist, M. and Tabrizi, S. J.
  78. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease.
     J Exp Med (2008) 205, 1869-1877.
    Bjorkqvist, M., Wild, E. J., Thiele, J., Silvestroni, A., Andre, R., Lahiri, N., Raibon, E., Lee, R. V., Benn, C. L., Soulet, D., Magnusson, A., Woodman, B., Landles, C., Pouladi, M. A., Hayden, M. R., Khalili-Shirazi, A., Lowdell, M. W., Brundin, P., Bates, G. P., Leavitt, B. R., Moller, T. and Tabrizi, S. J.
  79. Huntington’s disease phenocopies are clinically and genetically heterogeneous.
     Mov Disord (2008) 23, 716-720.
    Wild, E. J., Mudanohwo, E. E., Sweeney, M. G., Schneider, S. A., Beck, J., Bhatia, K. P., Rossor, M. N., Davis, M. B. and Tabrizi, S. J.
  80. Rapid eye movement sleep disturbances in Huntington disease.
     Arch Neurol (2008) 65, 482-488.
    Arnulf, I., Nielsen, J., Lohmann, E., Schiefer, J., Wild, E., Jennum, P., Konofal, E., Walker, M., Oudiette, D., Tabrizi, S. and Durr, A.
  81. Defective emotion recognition in early HD is neuropsychologically and anatomically generic.
     Neuropsychologia (2008) 46, 2152-2160.
    Henley, S. M., Wild, E. J., Hobbs, N. Z., Warren, J. D., Frost, C., Scahill, R. I., Ridgway, G. R., MacManus, D. G., Barker, R. A., Fox, N. C. and Tabrizi, S. J.
  82. Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood.
     Proc Natl Acad Sci U S A (2007) 104, 14424-14429.
    Runne, H., Kuhn, A., Wild, E. J., Pratyaksha, W., Kristiansen, M., Isaacs, J. D., Regulier, E., Delorenzi, M., Tabrizi, S. J. and Luthi-Carter, R.
  83. The differential diagnosis of chorea.
     Pract Neurol (2007) 7, 360-373.
    Wild, E. J. and Tabrizi, S. J.
  84. Plasma neurofilament heavy chain levels in Huntington’s disease.
     Neurosci Lett (2007) 417, 231-233.
    Wild, E. J., Petzold, A., Keir, G. and Tabrizi, S. J.
  85. Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates.
     J Proteome Res (2007) 6, 2833-2840.
    Dalrymple, A., Wild, E. J., Joubert, R., Sathasivam, K., Bjorkqvist, M., Petersen, A., Jackson, G. S., Isaacs, J. D., Kristiansen, M., Bates, G. P., Leavitt, B. R., Keir, G., Ward, M. and Tabrizi, S. J.
  86. Huntington’s disease phenocopy syndromes.
     Curr Opin Neurol (2007) 20, 681-687.
    Wild, E. J. and Tabrizi, S. J.
  87. Vasculitic presentation of staphylococcal meningitis.
     Arch Neurol (2007) 64, 1788-1789.
    Bentley, P., Qadri, F., Wild, E. J., Hirsch, N. P. and Howard, R. S.
  88. Predict-HD and the future of therapeutic trials.
     Lancet Neurol (2006) 5, 724-725.
    Wild, E. J. and Tabrizi, S. J.
  89. Deja vu in neurology.
     J Neurol (2005) 252, 1-7.
    Wild, E.
  90. Thyrotoxic periodic paralysis in a Maori patient.
     N Z Med J (2004) 117, U1204.
    Wild, E.
  91. Uterine diverticulum as a late complication of caesarean section.
     J Obstet Gynaecol (2003) 23, 88.
    Wild, E. and Gull, S.